Kura Oncology, Inc.

What they do

Kura develops and commercializes small-molecule precision medicines targeting cancer signaling pathways. Its lead product, KOMZIFTI (ziftomenib), is a menin inhibitor approved for adults with relapsed or refractory NPM1-mutated AML. The pipeline also includes ziftomenib in earlier AML settings and other indications, plus darlifarnib, a farnesyl transferase inhibitor, in combination with targeted therapies for solid tumors such as renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.

Revenue drivers

• KOMZIFTI (ziftomenib) net product revenue — In Q2 2026, net product revenue was $9.1 million, a 57% increase over Q1 2026, driven by approximately 115 new patient starts and over 250 total prescriptions.
• Collaboration and licensing payments — Management anticipates $180 million in collaboration payments, though specific partners and terms were not detailed in the provided excerpts.
• Potential future pipeline revenue — Revenue from darlifarnib and other pipeline candidates is not yet realized; these programs are in clinical development.

Recent performance

In Q2 2026, KOMZIFTI generated $9.1 million in net product revenue, up 57% from Q1 2026, with approximately 115 new patient starts (up 35%) and more than 250 total prescriptions (up 59%). The company reported quarterly revenues of $20.9 million for the three months ended June 30, 2026. For 2025, annual revenue was $67.5 million, while net loss widened to $278.7 million (EPS -$3.18). Cash, equivalents, and short-term investments totaled $519.0 million as of June 30, 2026.

Strategy

Kura aims to establish KOMZIFTI as the leading menin inhibitor in relapsed/refractory NPM1-mutated AML and to move it into earlier lines of treatment, including frontline combinations with intensive and non-intensive chemotherapy. The company is advancing registrational Phase 3 trials (KOMET-017) and combination studies (KOMET-008, KOMET-007) to expand ziftomenib's label. It is also developing darlifarnib as a precision combination platform with targeted therapies across major solid tumor indications. Management plans to build long-term value through a combination of internal development, partnerships, and collaborations while maintaining significant commercial rights.

Risks

• Commercial adoption risk — KOMZIFTI's revenue growth depends on physician and patient acceptance; despite early momentum, competition from other menin inhibitors could limit market share.
• Clinical development risk — Ziftomenib and darlifarnib are in ongoing trials; failure to demonstrate efficacy or safety could delay or prevent regulatory approvals for additional indications.
• Financial sustainability risk — The company had only $48.4 million in shareholder equity and $70.2 million in cash at June 30, 2026, and incurred a $278.7 million net loss in 2025, raising reliance on external funding.
• Regulatory and payer risk — As a newly approved product, KOMZIFTI faces pricing and reimbursement challenges with commercial and government payors; lack of favorable coverage could hinder uptake.

Outlook

Management expects to continue KOMZIFTI's commercial launch, with a focus on gaining majority share of new patient starts in the R/R NPM1-m AML menin inhibitor class. They anticipate enrollment in the KOMET-017 frontline registrational studies to progress, and plan to present additional data from KOMET-007 and other trials. The company also expects to receive $180 million in collaboration payments, which, combined with $519 million in cash, is intended to fund operations and pipeline advancement.